Travere Therapeutics Inc (TVTX)

$14.72 -0.50 (-3.29%)
Market Cap 1.35B
Revenue (ttm) 233.18M
Net Income (ttm) -321.55M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -137.90%
Debt to Equity Ratio 0.00
Volume 1,097,400
Avg Vol 1,813,412
Day's Range N/A - N/A
Shares Out 88.81M
Stochastic %K 12%
Beta 0.75
Analysts Strong Sell
Price Target $34.78

Latest News on TVTX

Travere Therapeutics, Inc. (TVTX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

Jun 4, 2025, 10:00 AM EDT - 2 days ago

Travere Therapeutics, Inc. (TVTX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

Travere Therapeutics to Present New FILSPARI® (sparsentan) Data at the 62nd ERA Congress

Jun 3, 2025, 4:30 PM EDT - 2 days ago

Travere Therapeutics to Present New FILSPARI® (sparsentan) Data at the 62nd ERA Congress

Bronstein, Gewirtz & Grossman, LLC Encourages Travere Therapeutics, Inc. (TVTX) Shareholders to Inquire about Securities Investigation

Jun 3, 2025, 10:00 AM EDT - 3 days ago

Bronstein, Gewirtz & Grossman, LLC Encourages Travere Therapeutics, Inc. (TVTX) Shareholders to Inquire about Securities Investigation

Bronstein, Gewirtz & Grossman, LLC Is Investigating Travere Therapeutics, Inc. (TVTX) And Encourages Shareholders to Connect

Jun 2, 2025, 10:00 AM EDT - 4 days ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Travere Therapeutics, Inc. (TVTX) And Encourages Shareholders to Connect

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Travere Therapeutics, Inc. (TVTX) And Encourages Shareholders to Reach Out

Jun 1, 2025, 10:00 AM EDT - 5 days ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Travere Therapeutics, Inc. (TVTX) And Encourages Shareholders to Reach Out

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Travere Therapeutics, Inc. (TVTX) and Encourages Investors to Learn More About the Investigation

May 30, 2025, 10:00 AM EDT - 7 days ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Travere Therapeutics, Inc. (TVTX) and Encourages Investors to Learn More About the Investigation

Travere Therapeutics, Inc. (TVTX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

May 29, 2025, 10:00 AM EDT - 8 days ago

Travere Therapeutics, Inc. (TVTX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC Is Investigating Travere Therapeutics, Inc. (TVTX) And Encourages Investors to Connect

May 28, 2025, 10:00 AM EDT - 9 days ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Travere Therapeutics, Inc. (TVTX) And Encourages Investors to Connect

Bronstein, Gewirtz & Grossman, LLC Encourages Travere Therapeutics, Inc. (TVTX) Stockholders to Inquire about Securities Investigation

May 27, 2025, 10:00 AM EDT - 10 days ago

Bronstein, Gewirtz & Grossman, LLC Encourages Travere Therapeutics, Inc. (TVTX) Stockholders to Inquire about Securities Investigation

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Travere Therapeutics, Inc. (TVTX) and Encourages Stockholders to Learn More About the Investigation

May 25, 2025, 10:00 AM EDT - 12 days ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Travere Therapeutics, Inc. (TVTX) and Encourages Stockholders to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC Encourages Travere Therapeutics, Inc. (TVTX) Investors to Inquire about Securities Investigation

May 23, 2025, 10:00 AM EDT - 14 days ago

Bronstein, Gewirtz & Grossman, LLC Encourages Travere Therapeutics, Inc. (TVTX) Investors to Inquire about Securities Investigation

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Travere Therapeutics, Inc. (TVTX) And Encourages Investors to Reach Out

May 22, 2025, 10:00 AM EDT - 15 days ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Travere Therapeutics, Inc. (TVTX) And Encourages Investors to Reach Out

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Travere Therapeutics, Inc. (TVTX) And Encourages Stockholders to Reach Out

May 21, 2025, 10:00 AM EDT - 16 days ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Travere Therapeutics, Inc. (TVTX) And Encourages Stockholders to Reach Out

Bronstein, Gewirtz & Grossman, LLC Is Investigating Travere Therapeutics, Inc. (TVTX) And Encourages Stockholders to Connect

May 20, 2025, 5:45 PM EDT - 16 days ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Travere Therapeutics, Inc. (TVTX) And Encourages Stockholders to Connect

Travere Therapeutics: Establishing A Position After Last Week's Selloff

May 20, 2025, 3:47 PM EDT - 16 days ago

Travere Therapeutics: Establishing A Position After Last Week's Selloff

Travere Therapeutics Announces FDA Acceptance of sNDA for FILSPARI® (sparsentan) in FSGS

May 15, 2025, 4:05 PM EDT - 21 days ago

Travere Therapeutics Announces FDA Acceptance of sNDA for FILSPARI® (sparsentan) in FSGS

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 12, 2025, 5:00 PM EDT - 24 days ago

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Travere Therapeutics to Participate at Upcoming Investor Conferences

May 7, 2025, 4:30 PM EDT - 4 weeks ago

Travere Therapeutics to Participate at Upcoming Investor Conferences

Travere Therapeutics, Inc. (TVTX) Q1 2025 Earnings Call Transcript

May 1, 2025, 11:07 PM EDT - 5 weeks ago

Travere Therapeutics, Inc. (TVTX) Q1 2025 Earnings Call Transcript

Travere Therapeutics Reports First Quarter 2025 Financial Results

May 1, 2025, 4:01 PM EDT - 5 weeks ago

Travere Therapeutics Reports First Quarter 2025 Financial Results

Travere Therapeutics and CSL Vifor Announce Standard EU Approval of FILSPARI® (sparsentan) for IgA Nephropathy

Apr 29, 2025, 7:01 AM EDT - 5 weeks ago

Travere Therapeutics and CSL Vifor Announce Standard EU Approval of FILSPARI® (sparsentan) for IgA Nephropathy

CSL Vifor and Travere Therapeutics announce standard EU approval for FILSPARI® in IgA Nephropathy

Apr 29, 2025, 2:00 AM EDT - 5 weeks ago

CSL Vifor and Travere Therapeutics announce standard EU approval for FILSPARI® in IgA Nephropathy

Travere Therapeutics to Report First Quarter 2025 Financial Results

Apr 24, 2025, 4:30 PM EDT - 6 weeks ago

Travere Therapeutics to Report First Quarter 2025 Financial Results

Travere Therapeutics to Present New FILSPARI® (sparsentan) Data at the National Kidney Foundation Spring Clinical Meetings 2025

Mar 31, 2025, 4:30 PM EDT - 2 months ago

Travere Therapeutics to Present New FILSPARI® (sparsentan) Data at the National Kidney Foundation Spring Clinical Meetings 2025

Travere Therapeutics Submits sNDA to FDA for Approval of FILSPARI® (sparsentan) for the Treatment of FSGS

Mar 17, 2025, 7:01 AM EDT - 2 months ago

Travere Therapeutics Submits sNDA to FDA for Approval of FILSPARI® (sparsentan) for the Treatment of FSGS

Travere Therapeutics, Inc. (TVTX) Q4 2024 Earnings Call Transcript

Feb 21, 2025, 8:17 AM EST - 3 months ago

Travere Therapeutics, Inc. (TVTX) Q4 2024 Earnings Call Transcript

Travere Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results

Feb 20, 2025, 4:01 PM EST - 3 months ago

Travere Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results

Travere Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results

Feb 13, 2025, 4:30 PM EST - 4 months ago

Travere Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results

Travere Therapeutics to Submit sNDA for FILSPARI® (sparsentan) in FSGS

Feb 11, 2025, 7:01 AM EST - 4 months ago

Travere Therapeutics to Submit sNDA for FILSPARI® (sparsentan) in FSGS

Travere Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Jan 6, 2025, 4:30 PM EST - 5 months ago

Travere Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Travere Therapeutics: Cautiously Bullish Based On Improving Revenue

Dec 19, 2024, 8:53 AM EST - 6 months ago

Travere Therapeutics: Cautiously Bullish Based On Improving Revenue

Homocystinuria Therapeutics Market Research 2024: Insights About 3+ Companies and 3+ Pipeline Drugs Featuring Travere Therapeutics and Syntis Bio

Dec 18, 2024, 9:39 AM EST - 6 months ago

Homocystinuria Therapeutics Market Research 2024: Insights About 3+ Companies and 3+ Pipeline Drugs Featuring Travere Therapeutics and Syntis Bio

Travere Therapeutics to Present at Upcoming Investor Conferences

Nov 25, 2024, 4:30 PM EST - 6 months ago

Travere Therapeutics to Present at Upcoming Investor Conferences

Travere Therapeutics Announces Pricing of Public Offering of Common Stock

Nov 7, 2024, 9:05 PM EST - 7 months ago

Travere Therapeutics Announces Pricing of Public Offering of Common Stock

Travere Therapeutics Announces Proposed Public Offering of Common Stock

Nov 7, 2024, 4:01 PM EST - 7 months ago

Travere Therapeutics Announces Proposed Public Offering of Common Stock

Travere Therapeutics, Inc. (TVTX) Q3 2024 Earnings Call Transcript

Oct 31, 2024, 3:13 PM EDT - 7 months ago

Travere Therapeutics, Inc. (TVTX) Q3 2024 Earnings Call Transcript

Travere Therapeutics Presents Data Reinforcing Clinical Benefit of FILSPARI® (Sparsentan) in IgAN and Late-Breaking Presentation in FSGS at ASN Kidney Week 2024

Oct 26, 2024, 7:01 AM EDT - 7 months ago

Travere Therapeutics Presents Data Reinforcing Clinical Benefit of FILSPARI® (Sparsentan) in IgAN and Late-Breaking Presentation in FSGS at ASN Kidney Week 2024

Travere Therapeutics to Report Third Quarter 2024 Financial Results

Oct 21, 2024, 4:30 PM EDT - 8 months ago

Travere Therapeutics to Report Third Quarter 2024 Financial Results

Travere Therapeutics and CSL Vifor Announce Swissmedic Approval of FILSPARI® (sparsentan) for the Treatment of IgA Nephropathy

Oct 17, 2024, 7:01 AM EDT - 8 months ago

Travere Therapeutics and CSL Vifor Announce Swissmedic Approval of FILSPARI® (sparsentan) for the Treatment of IgA Nephropathy

CSL Vifor and Travere Therapeutics Announce Swissmedic approval of FILSPARI® (sparsentan) for the treatment of IgA Nephropathy

Oct 17, 2024, 2:30 AM EDT - 8 months ago

CSL Vifor and Travere Therapeutics Announce Swissmedic approval of FILSPARI® (sparsentan) for the treatment of IgA Nephropathy

Travere Therapeutics to Present Abstracts at American Society of Nephrology (ASN) Kidney Week 2024

Oct 14, 2024, 4:30 PM EDT - 8 months ago

Travere Therapeutics to Present Abstracts at American Society of Nephrology (ASN) Kidney Week 2024